Reduced-intensity and non-myeloablative transplantation.
| Author, ref . | N . | Conditioning . | Age, y (range) . | HLA SIB/0ther donor . | Chemo-sensitive, % . | Median follow-up, mo . | PFS, % . | OS, % . | TRM, % . | Relapse, % . | cGVHD, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *Among 62 patients were several with transformed or aggressive follicular. | |||||||||||
| **Outcome in subset of patients with indolent (mostly follicular) and HLA identical sibling. | |||||||||||
| PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; Flu, fludarabine; Cy, cyclophosphamide; TBI, total-body irradiation; Bu, busulfan; Mel, melphalan; E, extensive. | |||||||||||
| Khouri22 | 47 | Flu Cy Rituxan | 53 (33–68) | 45/2 | 100 | 60 | 83 | 85 | 15 | 4 | 60 |
| Rezvani18 | 62* | (Flu)TBI | 54 (33–66) | 30/32 | 67 | 36 | – | – | 42 | 20 | – |
| Rezvani18 | 26*8 | (Flu)TBI | 54(33–66) | 26/0 | 67 | 36 | 54 | 67 | 23 | 14 | 47 E |
| Rodriguez24 | 16 | Flu Mel | 51 (20–67) | NS | NS | 20 | 40 | 53 | – | 19 | 76 |
| 50 E | |||||||||||
| Hari28 | 88 | Various | 51 (21–70) | 88/0 | 69 | 35 | 55 | 62 | 28 | 17 | 62 |
| Vigouroux27 | 73 | Various | 51 (33–66) | 63/10 | 74 | 37 | 52 | 55 | 15 | 40 | 43 |
| 20 E | |||||||||||
| Kusumi26 | 45 | Various | 45( 32–66) | – | 67 | 24 | – | 75 | – | 20 | – |
| Robinson25 | 52 | Various | 46 (27–65) | 91%/9% | 85 | – | 54 | 65 | 31 | 21 | – |
| Armand23 | 13 | Flu Bu | 51 (34–64) | 6/7 | 82 | 26 | 59 | 81 | 0 | 41 | 61 |
| Author, ref . | N . | Conditioning . | Age, y (range) . | HLA SIB/0ther donor . | Chemo-sensitive, % . | Median follow-up, mo . | PFS, % . | OS, % . | TRM, % . | Relapse, % . | cGVHD, % . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *Among 62 patients were several with transformed or aggressive follicular. | |||||||||||
| **Outcome in subset of patients with indolent (mostly follicular) and HLA identical sibling. | |||||||||||
| PFS indicates progression-free survival; OS, overall survival; TRM, treatment-related mortality; cGVHD, chronic graft-versus-host disease; Flu, fludarabine; Cy, cyclophosphamide; TBI, total-body irradiation; Bu, busulfan; Mel, melphalan; E, extensive. | |||||||||||
| Khouri22 | 47 | Flu Cy Rituxan | 53 (33–68) | 45/2 | 100 | 60 | 83 | 85 | 15 | 4 | 60 |
| Rezvani18 | 62* | (Flu)TBI | 54 (33–66) | 30/32 | 67 | 36 | – | – | 42 | 20 | – |
| Rezvani18 | 26*8 | (Flu)TBI | 54(33–66) | 26/0 | 67 | 36 | 54 | 67 | 23 | 14 | 47 E |
| Rodriguez24 | 16 | Flu Mel | 51 (20–67) | NS | NS | 20 | 40 | 53 | – | 19 | 76 |
| 50 E | |||||||||||
| Hari28 | 88 | Various | 51 (21–70) | 88/0 | 69 | 35 | 55 | 62 | 28 | 17 | 62 |
| Vigouroux27 | 73 | Various | 51 (33–66) | 63/10 | 74 | 37 | 52 | 55 | 15 | 40 | 43 |
| 20 E | |||||||||||
| Kusumi26 | 45 | Various | 45( 32–66) | – | 67 | 24 | – | 75 | – | 20 | – |
| Robinson25 | 52 | Various | 46 (27–65) | 91%/9% | 85 | – | 54 | 65 | 31 | 21 | – |
| Armand23 | 13 | Flu Bu | 51 (34–64) | 6/7 | 82 | 26 | 59 | 81 | 0 | 41 | 61 |